EP08.02-139 A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs

MLA

S. Lu, et al. “EP08.02-139 A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs.” Journal of Thoracic Oncology, vol. 17, Sept. 2022, p. S469. EBSCOhost, https://doi.org/10.1016/j.jtho.2022.07.822.

APA

S. Lu, Y. Zhang, G. Zhang, J. Zhou, S. Cang, Y. Cheng, G. Wu, P. Cao, D. Lv, H. Jian, C. Chen, X. Jin, P. Tian, K. Wang, G. Jiang, G. Chen, Q. Chen, H. Zhao, C. Ding, … S. Zhang. (2022). EP08.02-139 A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs. Journal of Thoracic Oncology, 17, S469. https://doi.org/10.1016/j.jtho.2022.07.822

Chicago

S. Lu, Y. Zhang, G. Zhang, J. Zhou, S. Cang, Y. Cheng, G. Wu, et al. 2022. “EP08.02-139 A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs.” Journal of Thoracic Oncology 17 (September): S469. doi:10.1016/j.jtho.2022.07.822.